No Data
Fujian Cosunter Pharmaceutical (300436.SZ): received a total of 50.3444 million yuan in government subsidies and rewards.
On December 10, Gulonhui reported that Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) announced that on December 10, 2024, it and its Innovative Drugs holding subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (referred to as "Guangsheng Zhonglin"), collectively received 50.3444 million yuan in government subsidies and rewards, all of which have been received. The aforementioned government subsidy is a special reward fund to accelerate the high-quality development of the Biomedical industry in Fujian Province and support the research and development of Innovative Drugs, as well as recognition of the company's achievements in Innovative Drugs R&D.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
We Think Fujian Cosunter Pharmaceutical (SZSE:300436) Has A Fair Chunk Of Debt
fujian cosunter pharmaceutical (300436.SZ): its subsidiary's innovative drug Tai Zhong Ding, a type of drug that fights against the new coronavirus, has been successfully included in the national medical insurance list.
Glonhui reported on November 28 that fujian cosunter pharmaceutical (300436.SZ) announced that on November 28, 2024, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2024)" will be released, coming into effect on January 1, 2025. Fujian fujian cosunter pharmaceutical co., ltd.'s innovative drugs holding subsidiary, fujian guangshengzhonglin biotechnology co., ltd., has passed the national medical insurance negotiation for its oral small molecule 3CL protease inhibitor innovative drug Atatewe tablets (project code: GST-HG171) / Ritonavir tablets combination packaging (product name: Taizhongding) for the first time.
The growing anxiety of Chiyao Mao
Where is the new way out?
Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.
Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%
